Marksans Pharma informs about press release

15 May 2025 Evaluate

Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

182.50 2.75 (1.53%)
02-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.30
Dr. Reddys Lab 1255.45
Cipla 1511.70
Zydus Lifesciences 917.00
Lupin 2108.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×